tDCS Associated to Blindsight Rehabilitation for the Treatment of Homonymous Hemianopsia
Launched by UNIVERSITY OF MILANO BICOCCA · Nov 3, 2016
Trial Information
Current as of May 11, 2025
Withdrawn
Keywords
ClinConnect Summary
The study design is a crossover AB BA. Treatment A consist in a cycle of blindsight training associated to tDCS, Treatment B consist in a a cycle of blindsight training alone.
During the blindsight training, the patient is asked to maintain central fixation and is exposed to visual stimuli in his blind hemifield. The patient task is detection and/or discrimination of stimuli.
During each session the patient is subjected to around 700 different stimuli variously associated in space and/or time.
One out of two blindsight training cycles is associated to tDCS treatment. Anodal tDCS is appli...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • The subject is able to give his informed consent
- • Stroke
- • Hemianopsia brain damage documented by means of TAC or RMN
- • Hemianopsia diagnosed by means automated visual field and Neurological Evaluation
- • Time from lesion at least six months
- • normal or corrected-to-normal visual acuity
- Exclusion Criteria:
- • Presence of Ophthalmologic neuropsychologic or psychiatric pathology
- • Global cognitive deficit,
- • Presence of other neurological pathology
- • Presence of cardiac peacemaker
- • Presence metallic or electronic items in the head or in the body
- • Story/familiarity of epilepsy, taking medications that can induce epileptic crisis
- • Severe heart disease
- • History of high alcohol consumption
- • Pregnancy
About University Of Milano Bicocca
The University of Milano-Bicocca is a distinguished academic institution renowned for its commitment to advancing research and education in the biomedical sciences. With a strong emphasis on interdisciplinary collaboration, the university fosters innovative clinical trials that aim to enhance patient care and medical outcomes. Its research initiatives are supported by state-of-the-art facilities and a dedicated team of experts, positioning the University of Milano-Bicocca as a leading sponsor in the realm of clinical trials, dedicated to translating scientific discoveries into practical applications for the benefit of society.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Carate Brianza, Cb, Italy
Patients applied
Trial Officials
Barbara M Matteo
Principal Investigator
Università degli Studi di Milano - Bicocca
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials